Figure 1: Nkg2d ligands contribute to the synergy of radiotherapy and anti-CTLA-4 mAbs
Back to the parent article
Thursday, September 20, 2012
Figure 1. Nkg2d ligands contribute to the synergy of radiotherapy and
anti-CTLA-4 mAbs. In mice with poorly immunogenic murine carcinoma cells
treated with an anti-CTLA-4 (CD152) antibody,
infiltrating cytolytic T cells did not form stable interactions with tumor
cells (I). Radiotherapy promoted stable interactions and tumor cell
elimination by inducing retinoic acid early inducible-1
(Rae-1) on tumor cells
(II). The interaction of Rae-1 on tumor cells with Nkg2d (killer cell lectin-like receptor
subfamily K member 1; Klrk1; Cd314) on infiltrating
T cells was required for antitumor activity in mice treated with the anti-CTLA-4
All contents Copyright © 1993-2015 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]